S&P 500 Healthcare Sector SEC Filings — May 07, 2026

07-05-2026

Definium Therapeutics reported Q1 2026 financial results with cash, cash equivalents, and investments of $373.4 million, down from $411.6 million at year-end 2025, sufficient to fund operations into 2028, alongside strong clinical progress including completed enrollments in Phase 3 Emerge (MDD, 149 participants) and Voyage (GAD, 214 participants) studies with topline data expected late 2Q and early 3Q 2026, respectively. However, net loss widened significantly to $77.1 million from $23.3 million YoY, driven by R&D expenses rising to $41.5 million (up $18.1 million YoY) due to DT120 ODT program costs and G&A expenses increasing to $17.7 million (up $8.9 million YoY) from stock-based compensation and personnel costs.

• ·Panorama study enrollment over 200 participants with screening closed; topline data late 3Q 2026.
• ·Ascend study site activation ongoing; first patient dosing anticipated 2Q 2026.
• ·Change in fair value of 2022 USD Financing Warrants contributed $20.0 million expense in Q1 2026.
• ·Common shares outstanding increased to 104,044,508 from 98,776,265 at Dec 31, 2025.

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

07-05-2026

Citizens Financial Services, Inc. reported net income of $10,376 thousand for the three months ended March 31, 2026, a 36.1% YoY increase from $7,621 thousand, supported by net interest income growth to $26,113 thousand (+13.5% YoY) and lower interest expense ($14,164 thousand vs. $16,012 thousand). However, total assets contracted 1.2% QoQ to $3,026,478 thousand, loans declined 2.3% QoQ to $2,275,328 thousand (net of $22,894 thousand allowance), and comprehensive income fell to $8,071 thousand from prior comprehensive gains due to a $2,305 thousand net OCI loss. Deposits rose 2.7% QoQ to $2,441,185 thousand, while borrowed funds dropped sharply 35.7% to $198,738 thousand.

• ·Noninterest-bearing deposits declined QoQ to $509,638 thousand from $516,657 thousand.
• ·Bank owned life insurance increased to $74,071 thousand from $51,501 thousand, reflecting $22,000 thousand purchase.
• ·EPS basic $2.16 for Q1 2026 vs. $1.59 YoY.
• ·Cash dividends paid $2,402 thousand at $0.500 per share.

07-05-2026

Ares Commercial Real Estate Corp (ACRE) reported a net loss of $9,605 thousand for the three months ended March 31, 2026, compared to net income of $9,345 thousand in the prior year period, primarily due to an $11,138 thousand provision for current expected credit losses and $3,340 thousand realized losses on loans, while interest income declined 9.4% YoY to $24,906 thousand. Total assets increased 13.5% QoQ to $1,836,304 thousand, driven by growth in loans held for investment to $1,629,366 thousand gross (net $1,492,536 thousand after higher CECL reserve of $136,830 thousand). However, stockholders' equity decreased 3.4% QoQ to $492,418 thousand, total revenue fell 10.0% YoY to $13,460 thousand, and net cash used in operating activities was $56,608 thousand versus provided $8,010 thousand YoY.

• ·Dividends declared per share remained flat at $0.15 for Q1 2026 vs Q1 2025.
• ·Weighted average unleveraged effective yield on loan portfolio was 5.8% as of March 31, 2026.
• ·Net cash used in operating activities $56,608 thousand in Q1 2026 vs provided $8,010 thousand in Q1 2025.
• ·Secured funding agreements increased to $1,182,096 thousand as of March 31, 2026 from $858,176 thousand as of Dec 31, 2025.

07-05-2026

Generate Biomedicines reported Q1 2026 financial results with cash, cash equivalents, and marketable securities of $516.6 million as of March 31, 2026, up significantly from $221.5 million at December 31, 2025, driven by $369.3 million in net IPO proceeds completed on March 2, 2026. The company advanced its clinical pipeline, including ongoing Phase 3 SOLAIRIA-1 and SOLAIRIA-2 trials for GB-0895 in severe asthma, site activation for GB-4362 (FDA Fast Track), and planned first dosing for GB-5267 in H2 2026. However, collaboration revenue declined 18% YoY to $7.2 million from $8.8 million, R&D expenses increased 24% to $57.8 million, G&A rose 34% to $13.5 million, and net loss widened to $61.7 million from $44.3 million.

• ·Existing cash sufficient to fund operations into first half of 2028; expects to require additional capital for long-term operations
• ·Non-cash stock-based compensation expense of $6.4 million in Q1 2026 vs $4.7 million in Q1 2025
• ·Total assets $625.7 million as of March 31, 2026 vs $330.2 million as of December 31, 2025

07-05-2026

News Corporation disclosed in its 8-K filing information provided to the Australian Securities Exchange (ASX) regarding its ongoing stock repurchase program, under which the company is authorized to acquire up to $1 billion in aggregate of its Class A common stock (NWSA) and Class B common stock (NWS). The disclosures are attached as Exhibits 99.1 and 99.2, covering daily transaction updates as required by ASX rules. The filing notes forward-looking statements about potential repurchases subject to market conditions and other factors.

• ·Date of earliest event reported: May 6, 2026
• ·Filing signed and dated: May 7, 2026
• ·Securities registered: Class A Common Stock (NWSA) and Class B Common Stock (NWS) on The Nasdaq Global Select Market

07-05-2026

Ponce Financial Group, Inc. reported Q1 2026 net income of $8,623 thousand, up 44.7% YoY from $5,959 thousand, driven by net interest income growth of 27.1% YoY to $28,226 thousand amid higher loan interest income, while total assets increased 2.4% QoQ to $3,300,757 thousand with loans up 3.8% to $2,698,649 thousand and deposits up 4.2% to $2,133,795 thousand. However, provision for credit losses deteriorated to a $1,656 thousand expense from a $285 thousand benefit YoY, non-interest income fell 14.2% YoY to $2,042 thousand, non-interest expense rose 2.1% to $17,240 thousand, and cash equivalents declined 7.1% QoQ to $117,246 thousand.

• ·Allowance for credit losses on loans: $26,238 thousand at March 31, 2026 (up from $25,449 thousand at Dec 31, 2025)
• ·Total non-performing loans recorded investment: $20,351 thousand at March 31, 2026 (down from $22,923 thousand at March 31, 2025)
• ·Basic EPS: $0.36 for Q1 2026 (up from $0.25 YoY)
• ·Stockholders' equity: $551,363 thousand at March 31, 2026 (up 1.8% QoQ from $541,549 thousand)

07-05-2026

For the quarter ended March 31, 2026, Invesco DB Precious Metals Fund reported total assets of $279.2M, up 8.3% from $257.7M at December 31, 2025, with shareholders' equity rising 8.4% to $279.0M and NAV per share increasing 6.2% to $109.41. Total income grew 46% YoY to $2.5M, driven by higher interest and dividends, and net realized gains on futures surged over 1,100% YoY to $3.7M; however, net income declined 44% YoY to $15.2M due to a 63% drop in unrealized gains on commodity futures contracts to $9.5M.

• ·Shares outstanding increased by 50,000 (2%) QoQ to 2,550,000 due to net purchases of $6.2M.
• ·Open long futures contracts: 440 COMEX Gold (notional $210.3M), 161 COMEX Platinum (notional $16.0M), 137 COMEX Silver (notional $52.6M).
• ·Net cash from operating activities: -$6.2M in Q1 2026 (vs -$20.0M in Q1 2025), offset by $6.2M from financing.

07-05-2026

Velocity Financial, Inc. reported net income attributable to common stockholders of $22,051 thousand for Q1 2026, up 18.2% YoY from $18,654 thousand, supported by net interest income growth of 17.0% to $43,920 thousand and total other operating income of $42,957 thousand. However, total operating expenses increased 28.8% YoY to $54,339 thousand, driven by higher compensation, professional fees, and REO expenses, while QoQ total assets grew 2.9% to $7,591,443 thousand but cash and cash equivalents fell to $87,054 thousand from $92,103 thousand and restricted cash dropped sharply to $24,996 thousand from $157,134 thousand. The loan portfolio expanded 5.1% QoQ to $7,105,538 thousand net, though loans at amortized cost declined to $1,951,030 thousand from $2,028,262 thousand.

• ·Diluted EPS $0.57 for Q1 2026, up from $0.51 in Q1 2025.
• ·Unsecured senior notes, net: $485,445 thousand as of March 31, 2026 (new issuance).
• ·Proceeds from unsecured financing: $500,000 thousand in Q1 2026.
• ·Net cash used in investing activities: $(351,372) thousand in Q1 2026.

07-05-2026

CION Investment Corp's Q1 2026 total investment income declined 11.7% YoY to $49,537 from $56,074, with net investment income dropping 33.2% to $12,864, amid higher interest expense of $24,413. However, the net decrease in net assets from operations improved to $23,031 ($0.45 per share) from $42,705 ($0.80 per share) YoY, though shareholders' equity fell 6.8% QoQ to $659,636 and NAV per share decreased 4.7% to $13.11 from $13.76. Total assets were $1,843,961, with investments at fair value down 0.7% QoQ to $1,799,474.

• ·Financing arrangements increased 2.9% QoQ to $1,158,183.
• ·Interest expense rose to $24,413 in Q1 2026 from $22,998 in Q1 2025.
• ·Net cash used in operating activities was $4,553 in Q1 2026 vs provided $6,095 in Q1 2025.
• ·Net unrealized depreciation was $36,132 in Q1 2026, improved from $64,251 in Q1 2025.

07-05-2026

BD (Becton, Dickinson and Company) (NYSE: BDX) announced the appointment of Vitor Roque as executive vice president and chief financial officer (CFO), effective May 7, 2026, following his role as interim CFO since December 2025. Roque, with over 25 years at BD, previously served as senior vice president, Finance and Corporate Financial Planning and Analysis, and led the separation of BD’s Biosciences & Diagnostic Solutions business ahead of schedule. Chairman and CEO Tom Polen praised Roque's deep institutional knowledge and execution experience to drive growth and shareholder value.

• ·Roque has held senior finance and operations roles across BD, including support for operations, manufacturing, regions, and business units.
• ·Roque has lived and worked in multiple countries, bringing global perspective.

07-05-2026

Lamar Advertising reported Q1 2026 net revenues of $528.0 million, up 4.5% YoY from $505.4 million, with Adjusted EBITDA rising 7.7% to $226.3 million and AFFO increasing 8.0% to $177.5 million. However, net income fell 26.9% to $101.8 million from $139.2 million due to the absence of a $67.7 million gain from the prior year's Vistar sale, and operating income declined to $146.1 million from $191.2 million. Free cash flow surged 25.8% to $152.4 million, while acquisition-adjusted net revenue grew 3.9% YoY.

• ·Cash flow provided by operating activities increased to $147.4 million from $127.7 million YoY.
• ·FFO increased 7.5% to $167.8 million from $156.1 million.
• ·Diluted AFFO per share was $1.00 for net income in Q1 2026 vs $1.35 in Q1 2025.
• ·Subsequent to quarter-end, revolver borrowings paid down by $40.0 million to $40.0 million outstanding; ARSP increased to $250.0 million.
• ·Conference call held on May 7, 2026 at 8:00 a.m. CT.

07-05-2026

Zoetis reported Q1 2026 revenue of $2.3 billion, up 3% YoY on a reported basis but flat organically operational, driven by an 8% decline in the U.S. segment (companion animals -11%) offset by 17% reported growth in International (10% organic operational). Net income was $601 million (flat YoY) and adjusted net income $646 million (+2% reported, +1% organic operational), amid challenges like price sensitivity and competition in pet care. The company revised FY2026 guidance to revenue of $9.680-$9.960 billion (2-5% organic operational growth) and adjusted diluted EPS of $6.85-$7.00.

• ·Entered definitive agreement to acquire Neogen’s animal genomics business, expected to close in H2 2026.
• ·Pipeline includes more than 12 potential blockbuster candidates.
• ·Recent approvals: Convenia new formulation in Canada, Apoquel Chewable in Thailand, ALPHA JECT micro 4 and Ketofen in Japan.

07-05-2026

NewAmsterdam Pharma reported Q1 2026 financial results showing cash, cash equivalents and marketable securities of $707.3 million, down from $728.9 million at December 31, 2025, with revenue flat at $3.0 million YoY, lower R&D expenses of $38.0 million (vs. $44.8 million) and SG&A of $23.5 million (vs. $27.2 million), but net loss widened to $48.4 million from $39.5 million YoY. The company provided positive clinical updates, including completed enrollment in REMBRANDT (323 patients) and PREVAIL (over 9,500 patients), planned PREVAIL interim analysis in 4Q2026 with results in 1Q2027, topline RUBENS data by year-end 2026, and new analyses from BROOKLYN/BROADWAY presented at ACC showing benefits in eGFR decline and renal events. Regulatory decisions on obicetrapib and FDC from EMA, UK, and Switzerland are expected in 2H26, with potential Menarini launches in 4Q26 in Germany and UK.

• ·Pooled BROOKLYN/BROADWAY analysis: obicetrapib associated with slower eGFR decline (-0.41 vs. -1.08 mL/min/1.73 m² with placebo; difference 0.67).
• ·Nominally fewer composite renal events over 12 months with obicetrapib.
• ·Share-based payment expenses in R&D: $6.8M Q1 2026 vs $5.2M Q1 2025; in SG&A: $11.2M vs $10.0M.
• ·Investor Day scheduled for August 5, 2026.
• ·New clinical trial for obicetrapib in early Alzheimer’s prevention expected to initiate in 2026.

07-05-2026

Six Flags Entertainment Corporation reported Q1 2026 net revenues up 12% YoY to $225.6 million, driven by 4% higher attendance at 2.9 million visits and 6% increased per capita spending to $69.26, despite 24 fewer operating days. However, net loss attributable to the company widened to $269 million from $220 million, although Adjusted EBITDA loss improved $48 million to $123 million. Year-to-date attendance through April rose 4% to 5.7 million on a same-park basis, with active pass base up 6% to 5 million units.

• ·Total liquidity increased to $462 million from $241 million YoY.
• ·Deferred revenues up 2% to $381 million.
• ·Operating costs and expenses decreased 12% or $50.4 million YoY.
• ·Leadership transitions: Amy Martin Ziegenfuss as CMO and Christopher Bennett as Chief Legal and Compliance Officer effective by June 3, 2026.

07-05-2026

Kelly Services reported Q1 2026 revenue of $1,040.7 million, down 10.7% YoY from $1,164.9 million, with underlying revenue decline of 3.3% (improved 60 bps sequentially) after 7.4% discrete impacts, while segments showed ETM down 13.2%, SET down 11.6%, and Education down 4.8%. Operating loss widened to $5.1 million from prior year earnings of $10.8 million, adjusted EBITDA fell 54.7% to $15.8 million (1.5% margin, down 150 bps), but adjusted SG&A declined 10.3% reflecting ongoing expense optimization. The company affirmed its FY2026 outlook for sequential revenue and adjusted EBITDA margin improvements, targeting Q2 revenue decline of 7-9% and margin of at least 2.5%, with H2 growth expected.

• ·Q1 2026 net loss of $5.9 million vs net earnings of $5.8 million in Q1 2025; diluted loss per share $0.17 vs $0.16 earnings.
• ·Year-to-date free cash flow $(26.5) million.
• ·Global Days Sales Outstanding 64 days (up from 61).
• ·Quarterly dividend of $0.075 per share payable June 2, 2026 to shareholders of record May 18, 2026.
• ·Q2 2026 outlook: revenue decline 7% to 9% (at least 100 bps underlying improvement), adjusted EBITDA margin at least 2.5%.

07-05-2026

Acacia Research Corporation reported Q1 2026 total revenue of $54.2 million, up 8% from the prior quarter but down 56% YoY to $54.2 million from $124.4 million primarily due to a 99% plunge in Intellectual Property Operations revenue. GAAP net loss was $15.7 million versus a $24.3 million profit in Q1 2025, with total company adjusted EBITDA of $1.6 million down sharply from $50.7 million YoY; however, operated segments delivered $6.8 million adjusted EBITDA and cash position remained strong at $329.9 million. Segment performance was mixed, with Energy Operations revenue up 2% YoY to $18.7 million but Industrial down 6% and Manufacturing down 3% YoY.

• ·Energy Operations adjusted EBITDA $7.7M in Q1 2026 vs $7.9M Q1 2025 (flat/down 2.8%)
• ·Industrial Operations adjusted EBITDA $1.4M in Q1 2026 vs $1.0M Q1 2025 (up 36%)
• ·Manufacturing Operations adjusted EBITDA $1.2M in Q1 2026 vs $2.4M Q1 2025 (down 51%)
• ·Parent indebtedness $0; consolidated non-recourse debt $90.5M ($59.5M Benchmark, $31.0M Deflecto)
• ·Book value per share $5.87 at Mar 31 2026
• ·Conference call held May 7, 2026 at 8:00 a.m. ET

07-05-2026

Harmony Biosciences reported Q1 2026 WAKIX net product revenue of $215.4 million, up 17% YoY from $184.7 million, reflecting strong demand despite seasonal market access headwinds, and reaffirmed FY2026 guidance of $1.0-$1.04 billion. However, net income declined to $32.5 million ($0.55/share) from $45.6 million ($0.78/share) due to higher cost of product sold (up to 20.7% of revenue) and R&D expenses (up 101% to $69.4 million from licensing upfronts). The company advanced IP protection with 6/7 ANDA settlements and new patents, pipeline milestones like Pitolisant GR NDA in Q2 2026, and added COO Peter Anastasiou and CFO Glenn Reicin.

• ·Filed patent infringement lawsuit against AET Pharma US and Sandoz in April 2026
• ·Acquired exclusive license to novel amorphous form of pitolisant patent out to 2042
• ·FDA approval of pediatric cataplexy indication for WAKIX on February 13, 2026
• ·Pitolisant GR NDA submission on track for Q2 2026; PDUFA Q1 2027
• ·Pitolisant HD Phase 3 topline data expected 2027
• ·BP-205 Phase 1 SAD PK data mid-2026; US IND mid-2026
• ·EPX-100 Phase 3 topline data 1H 2027 for Lennox-Gastaut and Dravet syndromes

07-05-2026

Edgewise Therapeutics reported Q1 2026 net loss of $49.0 million ($0.46 per share), widening from $40.8 million ($0.43 per share) YoY, driven by R&D expenses rising to $42.7 million (up from $36.8 million) and G&A to $11.5 million (up from $9.2 million), while cash reserves declined to $499.6 million from $530.1 million at Dec 31, 2025. Positive highlights include long-term MESA data showing functional stabilization in Becker MD up to 3.5 years and 99% enrollment from prior studies, with CIRRUS-HCM 12-week data expected Q2 2026 and pivotal GRAND CANYON results in Q4 2026. The company continues advancing programs in muscular dystrophies and cardiovascular indications amid increased spending.

• ·LYNX and FOX Phase 2 trials in Duchenne ongoing with data collection in open-label extensions.
• ·EDG-15400 Phase 1 ongoing in healthy adults; Phase 2 in HFpEF planned H2 2026.
• ·Total operating expenses Q1 2026: $54.1 million vs $46.0 million Q1 2025.
• ·Interest income Q1 2026: $5.1 million vs $5.2 million Q1 2025 (slight decline).

07-05-2026

Tull Financial Group, Inc. filed its 13F-HR report on May 7, 2026, disclosing institutional holdings as of March 31, 2026, with a total portfolio value of $223993746 across 31 positions held on a sole discretionary basis. The portfolio emphasizes ETFs including the largest position in SPDR S&P 500 ETF at $52784309, Vanguard Core Bond ETF at $37300583, and iShares Core MSCI EAFE ETF at $28966196, alongside individual stocks such as Apple Inc. at $860938 and Norfolk Southern Corp. at $989600. No prior period comparisons or changes are provided in the filing.

• ·All positions held as sole discretionary with no shared voting authority or put/call options.
• ·Report filed under SEC file number 028-24395.
• ·Filer address: 555 Belaire Avenue, Suite 130, Chesapeake, VA 23320.

07-05-2026

New England Research & Management, Inc. filed its 13F-HR report on May 7, 2026, disclosing equity holdings as of March 31, 2026, totaling $236625302 across 143 securities, all with sole discretionary voting authority. Top positions include Alphabet Inc. Class A ($11890606), Apple Inc. ($9606205), Johnson & Johnson ($7043050), Microsoft Corp. ($5555511), and AbbVie Inc. ($5548170). No prior period comparisons or changes from previous filings are provided in this report.

• ·Filing period end date: March 31, 2026
• ·All 143 positions held as SH SOLE (sole discretionary shares)
• ·Business address: 53 W. Jackson Blvd., Suite 603, Chicago, IL 60604

07-05-2026

Navellier & Associates Inc. filed its 13F-HR report on May 7, 2026, for the quarter ended March 31, 2026, disclosing 326 equity holdings with a total market value of $959530505. Notable positions include EMCOR Group, Inc. at $29836137, Comfort Systems USA, Inc. at $27307057, and Eli Lilly and Company at $25287988, all held solely with no other managers reported. The filing provides a current snapshot of the firm's discretionary portfolio without period-over-period comparisons.

• ·All 326 positions reported as SH SOLE with no shared management.
• ·Portfolio includes significant exposure to mining (e.g., Kinross Gold Corporation 525244 shares), technology (e.g., Apple Inc. 46610 shares), and energy sectors.
• ·Filing CIK: 0000872163; SEC file number: 028-02824.

07-05-2026

Principle Wealth Partners LLC filed its quarterly 13F-HR on May 07, 2026, reporting 380 equity holdings totaling $1,749,803,464 as of March 31, 2026. Top positions include JPMorgan Chase & Co COM (357768 shares valued at $105241069), Apple Inc COM (366709 shares valued at $93067188), and Microsoft Corp COM (114654 shares valued at $42441375). The filing provides a snapshot of holdings with no period-over-period changes or performance metrics disclosed.

• ·Filing period end date: March 31, 2026
• ·Address: 48 Wall Street, Madison, CT 06443
• ·Phone: (203) 318-8892

07-05-2026

FourThought Financial Partners, LLC disclosed 13F holdings totaling $1158909055 across 384 positions as of March 31, 2026. Top holdings include Microsoft Corp at $48909127 (132126 shares), Broadcom Inc at $46487256 (150196 shares), Nvidia Corporation at $34781636 (199436 shares), Chevron Corporation at $29191074 (141088 shares), and Vanguard S&P 500 ETF at $27613740 (46212 shares). No changes from prior periods are indicated in the filing.

• ·Filing date: May 07, 2026
• ·Report period end: March 31, 2026
• ·All positions reported as sole voting and sole discretion (SH SOLE 0 0)

07-05-2026

Kearny Financial Corp. reported net income of $10,137 thousand for the three months ended March 31, 2026, up 52.5% YoY from $6,648 thousand, with net interest income rising 15.2% YoY to $39,236 thousand due to an 11.8% decline in interest expense to $39,933 thousand. For the nine months ended March 31, 2026, net income increased 50.6% YoY to $29,092 thousand, supported by 16.0% higher net interest income at $114,909 thousand. However, total assets contracted 1.7% to $7,607,656 thousand from June 30, 2025, net loans receivable fell 0.6% to $5,734,458 thousand, and interest income was slightly down 0.2% YoY for the quarter.

• ·Provision for credit losses was $391 thousand for the three months ended March 31, 2026, up from $366 thousand YoY.
• ·Non-interest expense increased 6.3% YoY to $32,299 thousand for the three months ended March 31, 2026.
• ·Basic EPS was $0.16 for the three months ended March 31, 2026, up from $0.11 YoY.
• ·Total stockholders' equity rose 2.3% to $763,032 thousand as of March 31, 2026 from June 30, 2025.

07-05-2026

Patrick M. Sweeney & Associates, Inc., an Illinois-based investment advisor, filed its 13F-HR on May 7, 2026, disclosing equity holdings as of March 31, 2026, with a total portfolio value of $155,993,964 across 164 positions, all held with sole voting and dispositive power. Top holdings by value include Apple Inc. ($9,401,289, 37,044 shares), JPMorgan Chase & Co. ($6,949,419, 23,625 shares), Bank of America Corp. ($6,190,339, 126,981 shares), and Merck & Co. Inc. ($5,780,813, 48,057 shares). The filing provides a snapshot of holdings with no period-over-period changes indicated.

• ·Filing period end date: 2026-03-31
• ·Filing date: 2026-05-07
• ·All 164 positions reported as SH SOLE (sole voting and dispositive power)

07-05-2026

Allium Financial Advisors, LLC filed its 13F-HR disclosing $124,709,776 in total portfolio value across 79 holdings as of March 31, 2026. Top holdings include iShares TR MSCI EMG MKT ETF ($16,624,818), Apple Inc. ($5,743,566), and NVIDIA Corporation ($5,557,127), with significant allocations to technology stocks and ETFs. No period-over-period changes are detailed in this snapshot filing.

• ·Filing date: May 07, 2026
• ·Report period end: March 31, 2026
• ·Apple Inc shares: 22,631
• ·NVIDIA Corporation shares: 31,864

07-05-2026

For the three months ended March 27, 2026, Jones Financial Companies LLLP reported total revenue of $4,718M, up 11.9% YoY from $4,218M, primarily driven by asset-based fee revenue growth of 17.9% to $3,882M, while trade revenue grew modestly 1.6% to $450M and account/activity fees remained flat at $187M. However, interest and dividends revenue declined 15.2% YoY to $229M, other revenue swung to a $30M loss from a $25M gain, and total operating expenses increased 13.2% to $4,136M, resulting in income before allocations up only 5.3% to $541M; per unit income allocated to limited partners dipped 2.6% to $37.87. Total assets fell 4.9% QoQ to $29,011M from $30,508M, and net cash used in operating activities was $735M versus $96M provided YoY.

• ·Client receivables increased to $5,577M from $5,369M QoQ.
• ·Accrued compensation and benefits decreased to $2,887M from $3,600M QoQ.
• ·Reserve for anticipated withdrawals declined to $451M from $678M QoQ.
• ·Net cash decrease was $846M in Q1 2026 versus $597M YoY.
• ·Weighted average limited partner units declined to 1,728,647 from 1,736,683 YoY.

07-05-2026

Federal Home Loan Bank of Cincinnati reported Q1 2026 net income of $100,456 thousand, a 31% YoY decline from $145,103 thousand, driven by lower net interest income of $157,872 thousand (down 16% YoY from $187,843 thousand) amid reduced interest income from advances and investment securities. Total assets expanded 5% QoQ to $136,229,265 thousand as of March 31, 2026 from $129,405,050 thousand at December 31, 2025, supported by a 12% QoQ increase in advances to $78,587,557 thousand. Capital grew to $6,997,434 thousand, up 7% QoQ.

• ·Non-interest income declined sharply to $395 thousand from $17,089 thousand YoY due to net losses on trading securities of $(23,233) thousand.
• ·Non-interest expense increased 6% YoY to $46,470 thousand.
• ·Shares outstanding: 58,791,473 Class B as of April 30, 2026.

07-05-2026

Action Point Financial Planning, LLC, a Michigan-based investment advisor, filed its quarterly 13F-HR report disclosing 242 equity positions with a total market value of $112,097,117 as of March 31, 2026. The portfolio consists primarily of ETFs from American Century, Dimensional ETF Trust, and iShares, alongside smaller positions in individual stocks such as Apple Inc (approximately 1,918 shares), NVIDIA Corporation (3,878 shares), Berkshire Hathaway Inc Cl B (458 shares), and Caterpillar Inc (680 shares). No prior period data is included for comparison, resulting in a neutral snapshot of holdings with no reported changes.

• ·Filing date: May 07, 2026
• ·Report period end: March 31, 2026
• ·Filer CIK: 0002116119
• ·Business address: 124 Fulton Street East, Suite 200, Grand Rapids, MI 49503
• ·All positions reported as sole discretionary voting power (SH SOLE)

07-05-2026

Disciplina Capital Management LLC filed its quarterly 13F-HR report on May 7, 2026, for the period ended March 31, 2026, disclosing holdings across 69 securities with a total market value of $943,624,095. The portfolio is diversified with significant allocations to fixed income and broad market ETFs such as iShares Core US Aggregate Bond ETF ($222,150,618) and iShares Total US Stock Market ETF ($191,415,950), alongside individual equities including Apple Inc., Amazon.com Inc., and Nvidia Corp. The report was signed by Matthew Wright, President/CIO.

• ·Largest individual equity holding: Home Depot Inc with 3,153 shares valued at $1,036,918
• ·Significant ETF positions include WisdomTree Floating Rate Treasury ETF (665,797 shares, $33,516,221) and iShares Core MSCI EAFE ETF (887,509 shares, $80,346,190)
• ·Firm address: 21 Platform Way South, 14th Floor, Nashville, TN 37203

07-05-2026

D'Orazio & Associates, Inc., a Vienna, VA-based investment adviser, filed Form 13F-HR on May 07, 2026, disclosing holdings in 299 securities valued at a total of $772125693 thousand as of March 31, 2026. The portfolio consists exclusively of sole discretionary shares in a diverse mix of common stocks and ETFs, including major positions in Booz Allen Hamilton, various iShares and Invesco ETFs, and tech leaders like Apple, Microsoft, Alphabet, and Amazon. No period-over-period changes are reported in this filing, with only minor exceptions of one small PRN call in Booz Allen Hamilton and a warrant position in Heartbeam Inc.

• ·All positions reported as SH SOLE discretionary with zero voting authority in other categories, except 700 PRN Call shares in Booz Allen Hamilton and 16000 SH in Heartbeam Inc warrant expiring 10/31/202
• ·Portfolio period end date: 2026-03-31; filing as-of date: 2026-05-07

07-05-2026

Regions Financial Corp reported net income of $559 million for Q1 2026, up 14% YoY from $490 million, driven by higher net interest income of $1,248 million (up 4.5% YoY) and non-interest income of $625 million (up 6% YoY), alongside a lower provision for credit losses at $91 million versus $124 million. However, total interest income declined 1.3% YoY to $1,702 million, mortgage income fell to $32 million from $40 million, and comprehensive income dropped sharply to $376 million from $1,126 million due to $183 million in other comprehensive losses. Total assets grew 1.2% QoQ to $160,741 million with net loans up 2.4% to $96,399 million, but shareholders' equity decreased 1.4% QoQ to $18,779 million.

• ·Diluted EPS $0.62 in Q1 2026 vs $0.51 in Q1 2025.
• ·Non-interest expense increased to $1,068M from $1,039M YoY.
• ·Residential mortgage servicing rights at fair value declined to $954M from $970M QoQ.

07-05-2026

Chemung Financial Corp reported Q1 2026 net income of $9.2 million, up 53% YoY from $6.0 million, driven by 19% higher net interest income to $23.6 million and a lower provision for credit losses at $0.6 million versus $1.1 million. However, non-interest expenses rose 3% to $17.5 million, comprehensive income declined to $9.5 million from $14.2 million due to lower unrealized gains on AFS securities, and total interest expense on borrowed funds increased to $1.5 million from $0.7 million YoY. Total assets grew 1% QoQ to $2.75 billion, with loans up 2% to $2.29 billion net and deposits up 2% to $2.31 billion.

• ·Basic and diluted EPS $1.91 in Q1 2026 vs $1.26 in Q1 2025.
• ·Cash dividends declared $0.34 per share in Q1 2026 vs $0.32 in Q1 2025.
• ·Treasury stock shares reduced to 491,250 at March 31, 2026 from 519,079 at Dec 31, 2025.

07-05-2026

Clark Financial Services Group Inc /BD filed a 13F-HR report disclosing total equity holdings of $192,441,545 across 187 positions as of March 31, 2026. The portfolio features heavy allocations to ETFs including Vanguard S&P 500 ETF ($20,594,232), SPDR S&P 500 ETF Trust ($19,137,606), and iShares S&P 500 Growth ETF ($11,644,675), alongside individual stocks such as Apple Inc. (total ~$7,430,686) and RTX Corporation ($7,092,354). No period-over-period changes or performance metrics are provided in the filing.

• ·Holdings include both sole discretionary (majority) and other managed accounts (OTR).
• ·Portfolio diversified across tech (e.g., NVIDIA, Microsoft), ETFs, financials, and healthcare sectors.
• ·Filing submitted May 07, 2026, for quarter ended March 31, 2026.

07-05-2026

BOK Financial Corp held its annual shareholder meeting on May 5, 2026, where all 15 director nominees were elected with For votes ranging from 44,558,125 to 55,253,074 shares and consistent broker non-votes of 5,359,045 shares. Shareholders overwhelmingly ratified Ernst & Young LLP as auditors for the fiscal year ending December 31, 2026, with 57,510,776 For votes against 477,573 Against and 14,518 Abstain/Withheld. An advisory vote to approve named executive officer compensation passed with 54,864,505 For votes against 339,765 Against and 197,745 Abstain/Withheld.

• ·Director election votes - Alan S. Armstrong: For 44,558,125, Withheld 10,843,890
• ·Director election votes - George B. Kaiser: For 47,688,553, Withheld 7,713,462 (lowest For among nominees)
• ·Auditor ratification: Against 477,573, Abstain/Withheld 14,518
• ·Say-on-pay advisory vote: Against 339,765, Abstain/Withheld 197,745

07-05-2026

Crewe Advisors LLC filed its 13F-HR on May 7, 2026, reporting total holdings of $1,171,736,275 across 1,038 positions as of March 31, 2026. Top holdings include Berkshire Hathaway Inc. Del Cl A (56 shares valued at $40,215,840), Apple Inc. (105,084 shares valued at $26,669,222), and Chevron Corporation (104,185 shares valued at $21,555,937). No prior period data is provided for comparisons, and all positions are reported as sole discretionary.

• ·Filing date: May 07, 2026
• ·Report period end date: March 31, 2026
• ·All positions held as sole discretionary voting authority
• ·Business address: 650 S. Main Street, Suite 700, Salt Lake City, UT 84101

07-05-2026

CoreCivic reported Q1 2026 revenue of $614,729 thousand, up 25.8% YoY from $488,627 thousand, with net income rising 51.0% to $37,916 thousand and EPS increasing to $0.38 from $0.23. However, operating cash flow declined sharply to $13,770 thousand from $44,484 thousand due to unfavorable working capital changes, including higher accounts receivable and lower payables. The company boosted long-term debt to $1,380,955 thousand from $1,205,037 thousand, partly funding $55,069 thousand in stock repurchases.

• ·Revolving Credit Facility balance increased to $425,000 thousand at 7.6% interest.
• ·Total debt $1,406,452 thousand, with significant maturities in 2028 ($522,995 thousand) and 2029 ($507,985 thousand).
• ·Share repurchases retired 2,899 thousand shares for $54,070 thousand.
• ·Capital expenditures totaled $23,269 thousand in Q1 2026.